PureTech to Present at the Leerink Partners Global Healthcare Conference

Rhea-AI Summary

PureTech Health (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company focused on developing treatments for devastating diseases, has announced its participation in the Leerink Partners Global Healthcare Conference.

The company's Chief Executive Officer, Bharatt Chowrira, PhD, JD, and Co-founder and President, Eric Elenko, PhD, will engage in a fireside chat on Tuesday, March 11, 2025, at 1:00pm EDT.

Investors and interested parties can access a webcast of the presentation through PureTech's investor relations website at https://investors.puretechhealth.com.

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Bharatt Chowrira, PhD, JD, Chief Executive Officer, and Eric Elenko, PhD, Co-founder and President, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:00pm EDT. A webcast of the presentation will be available at https://investors.puretechhealth.com.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our upcoming presentation at the Leerink Partners Global Healthcare Conference and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250225473235/en/

PureTech

Public Relations

publicrelations@puretechhealth.com

Investor Relations

IR@puretechhealth.com



UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com



US Media

Justin Chen

+1-609-578-7230

jchen@tenbridgecommunications.com

Source: PureTech Health plc

FAQ

When is PureTech (PRTC) presenting at the Leerink Partners Global Healthcare Conference?

PureTech (PRTC) will present at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:00pm EDT.

Who will represent PureTech (PRTC) at the Leerink Partners Conference in 2025?

Bharatt Chowrira, PhD, JD, Chief Executive Officer, and Eric Elenko, PhD, Co-founder and President, will represent PureTech at the conference.

How can investors watch PureTech's (PRTC) presentation at the Leerink Partners Conference?

Investors can watch the webcast of PureTech's presentation through the company's investor relations website at https://investors.puretechhealth.com.

What type of presentation will PureTech (PRTC) deliver at the Leerink Partners Healthcare Conference?

PureTech will participate in a fireside chat format presentation at the conference.

What exchanges is PureTech (PRTC) listed on according to the March 2025 conference announcement?

PureTech is listed on Nasdaq (PRTC) and the London Stock Exchange (LSE: PRTC).